


Promotion effect of GSK3 β palmitoylation in glioblastoma

May 27 2022, by Zhang Nannan



Schematic illustration of the mechanism of ZDHHC4-mediated GSK3 β palmitoylation promotes GBM TMZ-resistance. Credit: Zhao Chenggang

According to a recent study published on *Oncogenesis*, a team led by Prof. Fang Zhiyou and Pro. Chen Xueran from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences (CAS) found, for the first time, that palmitoylation regulated the activity of glycogen synthase kinase 3 β (GSK3 β), activating the EZH2–STAT3 pathway and promoting glioblastoma (GBM) temozolomide (TMZ) resistance and glioblastoma stem cells (GSC) self-renewal.

Due to the [blood-brain barrier](#), TMZ is currently the most commonly used chemotherapeutic drug for the clinical treatment of GBM. However, the mechanism of TMZ resistance is not completely clear. Recent data have implicated the involvement of protein palmitoylation dysfunctions in GBM progression and chemotherapy resistance in some tumor types. Therefore, palmitoylation is a valuable research direction to address TMZ resistance.

In this study, scientists discovered novel mechanistic evidence relating signaling pathways with GSC in GBM. They also investigated the role of palmitoyltransferase ZDHHC4 in activating GSK3 β and its target, EZH2/STAT3 in GSC self-renewal.

As a result, ZDHHC4-GSK3 β -STAT3 axis, which was involved in TMZ resistance in GBM, was identified. They found that phosphorylation of EZH2/STAT3 signaling was downregulated by reducing ZDHHC4 expression or GSK3 β palmitoylation, thereby inhibiting GSC self-renewal, TMZ chemotherapy resistance, and tumorigenesis.

"This study," said Zhao Chenggang, who conducted the research,

"identified ZDHHC4 as a potential GBM diagnostic marker and drug target, deepened the understanding of GBM chemotherapy resistance and paved the way for targeted therapies for GBM."

More information: Chenggang Zhao et al, GSK3 β palmitoylation mediated by ZDHHC4 promotes tumorigenicity of glioblastoma stem cells in temozolomide-resistant glioblastoma through the EZH2–STAT3 axis, *Oncogenesis* (2022). [DOI: 10.1038/s41389-022-00402-w](https://doi.org/10.1038/s41389-022-00402-w)

Provided by Chinese Academy of Sciences

Citation: Promotion effect of GSK3 β palmitoylation in glioblastoma (2022, May 27) retrieved 3 July 2023 from <https://medicalxpress.com/news/2022-05-effect-gsk3-palmitoylation-glioblastoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.